BMED
Future Health ETF
BMED is actively managed to invest in global equities in the health sciences industry.
Global
EQUITY
Active
MANAGEMENT STYLE
$ 9.9 M
ASSETS UNDER MGMT
85 bp
EXPENSES
Fund Basics
| Inception date | Sep 29, 2020 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| JOHNSON & JOHNSON | 7.9 % |
| GILEAD SCIENCES INC | 5.5 % |
| EDWARDS LIFESCIENCES CORP | 4.8 % |
| AMGEN INC | 4.5 % |
| MERCK & CO. INC. | 4.1 % |
| BIOGEN IDEC INC | 3.6 % |
| WUXI BIOLOGICS (CAYMAN) INC. | 3.2 % |
| WATERS CORP | 3.2 % |
| METTLER-TOLEDO INTERNATIONAL | 3.1 % |
| INTUITIVE SURGICAL INC | 3.0 % |
Constituent Breakdown
| Number of holdings | 55 |
| Herfindahl-Hirschman Index | 312 |
| Wgt avg mkt cap (mns) | $80,116 |
| Large cap (>$10bn) | 72.5% |
| Mid cap ($2-10bn) | 15.6% |
| Small cap (<$2bn) | 4.1% |
| Developed mkts. | 92.5% |
| Emerging mkts. | 1.4% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 78.1 % |
 |
SWITZERLAND | 5.2 % |
 |
CHINA | 3.2 % |
 |
NETHERLANDS | 2.9 % |
 |
BRITAIN | 1.6 % |
 |
BELGIUM | 1.6 % |
 |
ISRAEL | 1.2 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -7.5% | 15.5% | 7.2% | 4.9% | -1.2% | -- | -- | 1.7% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -- | -- | 0.0% |
| Total Returns | -7.5% | 15.5% | 7.2% | 4.9% | -1.2% | -- | -- | 1.7% | Ann. Volatility | 17.2% | 15.6% | 16.7% | 15.7% | 17.5% | -- | -- | 17.9% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.72 | 32% |
| MSCI EAFE | 0.70 | 40% |
| MSCI Emg Mkts | 0.43 | 23% |
Liquidity Measures
| Avg. volume (000) | 3 |
| ADV traded (mns) | $0 |
| Turnover | 0.8% |
| Avg. Bid/Ask (% of price) | 0.26% |
Technical Indicators
| 30d moving avg. (EMA) | $28.29 |
| Relative strength (RSI) | 39 |
| MACD/Signal | -0.35/-0.33 |
| Bollinger Bands (Upper/Lower) | $29.07/$27.08 |
| Short interest (% of AUM) | 1.9% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. BMED |
Expenses vs. BMED |
ALTAR Score™ vs. BMED |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR | 37.0% | -77 bp | +6.3% |
| FHLC | Fidelity MSCI Health Care Index ETF | 35.9% | -77 bp | +5.0% |
| VHT | Vanguard Health Care ETF | 35.6% | -76 bp | +4.7% |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 34.7% | -45 bp | +6.3% |
| HRTS | Tema Heart & Health ETF | 34.3% | -10 bp | +2.3% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 32.9% | -25 bp | +6.6% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 32.8% | -10 bp | +0.5% |
| BBH | VanEck Biotech ETF | 30.5% | -50 bp | +3.7% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 25.1% | -66 bp | -0.8% |
| FMED | Fidelity Disruptive Medicine ETF | 25.1% | -35 bp | -2.3% |
Risk and Returns: BMED vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/17/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
1.1%
ALTAR SCORE™
11st
PERCENTILE
AVOID
ETFRC RATING
There are 584 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. BMED's ALTAR Score™ is approximately -1.2 standard
deviations above the category average. This places BMED in the 11st percentile
among funds in the category.
Sell-Side Consensus
$33.83
PRICE TARGET
+24.1%
UPSIDE